Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2002
Business Overview: BMS is a major producer of pharmaceuticals and healthcare products operating in three segments: Pharmaceuticals (81% of sales), Nutritionals (10%), and Other Healthcare (9%). The year was defined by significant accounting restatements regarding revenue recognition for wholesaler sales, major litigation settlements, and the integration of the DuPont Pharmaceuticals acquisition.
Key Financial Metrics
| Metric | 2002 | 2001 | Change |
|---|---|---|---|
| Net Sales | $18,119 million | $17,987 million | +1% |
| Earnings from Continuing Operations | $2,034 million | $2,043 million | -0.4% |
| Diluted EPS (Continuing Ops) | $1.05 | $1.04 | +1% |
| Net Earnings (Total) | $2,066 million | $4,834 million | -57% |
| Operating Cash Flow | $957 million | $5,402 million | -82% |
| Long-Term Debt | $6,261 million | $6,237 million | +0.4% |
| Cash & Equivalents | $3,978 million | $5,500 million | -28% |
| Working Capital | $1,755 million | $2,140 million | -18% |
Note: 2001 Net Earnings included a $2.6 billion after-tax gain from the sale of Clairol (discontinued operations), which is not present in 2002.
Material Changes vs. Prior Period
- Accounting Restatement: The Company restated financial statements for 1999 through Q2 2002. This was due to the improper recognition of revenue on sales to major wholesalers (Cardinal and McKesson) which should have been accounted for under the consignment model. This adjustment reduced 2001 sales by $1.0 billion and 2000 sales by $475 million.
- Product Performance:
- PLAVIX*: Sales surged 61% to $1.89 billion.
- PRAVACHOL: Sales grew 8% to $2.27 billion.
- GLUCOPHAGE* IR: Sales collapsed 88% to $220 million due to generic competition.
- TAXOL®: Sales fell 23% to $857 million, with domestic sales dropping 70% due to generic entry.
- Acquisitions & Divestitures: Completed the $7.8 billion acquisition of DuPont Pharmaceuticals (Oct 2001). Completed the sale of Clairol (Nov 2001) and spin-off of Zimmer (Aug 2001), both reported as discontinued operations.
- Impairment Charges: Recorded a $379 million impairment charge for its investment in ImClone Systems.
Guidance, Outlook, and Risks
Management Commentary & Outlook
Management expects 2003 sales growth to better reflect underlying prescription trends as the wholesaler inventory workdown concludes. Key growth drivers include PLAVIX*, AVAPRO*, PRAVACHOL, and the new product ABILIFY*. The Company projects fully diluted earnings per share for 2003 to be between $1.60 and $1.65, excluding non-comparable items.
Significant Risks and Contingencies
- Legal Proceedings:
- TAXOL® & BUSPAR Litigation: Reached agreements in principle to settle antitrust litigation. Expected settlements total $670 million ($135 million for TAXOL, $535 million for BUSPAR), fully accrued in 2002.
- SEC & DOJ Investigations: Ongoing investigations into wholesaler inventory practices, accounting reserves, and the ImClone investment. The Company states it has recorded all necessary adjustments but cannot assess final outcomes.
- Securities Class Actions: Pending suits regarding VANLEV, wholesaler incentives, and ImClone.
- Internal Controls: Auditors identified two "material weaknesses" in internal controls related to financial reporting and management review. The Company has hired a new CFO, restaffed the controller position, and implemented new certification processes.
- Pension Obligations: Market declines increased pension expense. The Company expects pension costs to rise by approximately $120 million in 2003 due to lower discount rates and asset returns.
Investor Verification Checklist
- Restatement Impact: Verify the full extent of the revenue recognition adjustments and the timeline for the complete workdown of consignment inventory.
- Legal Settlements: Confirm the final approval of the $670 million TAXOL/BUSPAR settlements and any potential for additional claims from health insurers.
- Regulatory Investigations: Monitor the status of SEC and DOJ investigations regarding accounting practices and the ImClone transaction for potential fines or further restatements.
- Patent Expirations: Assess the impact of upcoming patent expirations for MONOPRIL, SERZONE, and GLUCOPHAGE* XR in 2003.
- ImClone Investment: Review the status of the ImClone investment and the potential application of FIN 46 (Variable Interest Entities) which could require consolidation.